Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta …
H Liu, Y Wu, T Lv, Y Yao, Y Xiao, D Yuan, Y Song - PLoS one, 2013 - journals.plos.org
Background The aim of this study was to assess the role of skin rash in predicting the
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the …
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis …
F Petrelli, K Borgonovo, M Cabiddu, V Lonati, S Barni - Lung cancer, 2012 - Elsevier
BACKGROUND: Dermatological toxicity, usually in the form of acneiform rash, is frequently
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
observed in non-small-cell lung cancer (NSCLC) patients treated with anti-EGF receptor …
Synthesis, anticancer activity and molecular modeling studies of 1, 2, 4-triazole derivatives as EGFR inhibitors
HAM El-Sherief, BGM Youssif, SNA Bukhari… - European journal of …, 2018 - Elsevier
A series of novel compounds carrying 1, 2, 4-triazole scaffold were prepared and evaluated
for their antiproliferative activities against NCI 60 cell line. Compounds 10 (a, c), 11 (ad), and …
for their antiproliferative activities against NCI 60 cell line. Compounds 10 (a, c), 11 (ad), and …
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo [3, 2-d] …
T Ishikawa, M Seto, H Banno, Y Kawakita… - Journal of medicinal …, 2011 - ACS Publications
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth
factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other …
factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other …
The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung …
MH Chang, JS Ahn, J Lee, KH Kim, YH Park, J Han… - Lung Cancer, 2010 - Elsevier
BACKGROUND: Pemetrexed is one of the standard second-line therapies in advanced non-
small cell lung cancer (NSCLC). Currently, there are no standard cytotoxic treatments …
small cell lung cancer (NSCLC). Currently, there are no standard cytotoxic treatments …
Design and synthesis of pyrrolo [3, 2-d] pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo …
Y Kawakita, K Miwa, M Seto, H Banno, Y Ohta… - Bioorganic & medicinal …, 2012 - Elsevier
During the course of our studies on a novel HER2/EGFR dual inhibitor (TAK-285), we found
an alternative potent pyrrolo [3, 2-d] pyrimidine compound (1a). To enhance the …
an alternative potent pyrrolo [3, 2-d] pyrimidine compound (1a). To enhance the …
Synthesis, crystallography, DFT, MTT assay, and molecular docking studies of an exocyclic double-bonded crystalline chalcone
Abstract A bicyclic chalcone 2-(4-methoxybenzylidene)-3, 4-dihydro-2H-naphthalen-1-one
(MDN) with an exocyclic double bond was synthesized using Claisen-Schmidt condensation …
(MDN) with an exocyclic double bond was synthesized using Claisen-Schmidt condensation …
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors
W Hou, Y Ren, Z Zhang, H Sun, Y Ma, B Yan - Bioorganic & Medicinal …, 2018 - Elsevier
A series of novel quinazoline derivatives bearing various C-6 benzamide substituents were
synthesized and evaluated as EGFR inhibitors, and most showed significant inhibitory …
synthesized and evaluated as EGFR inhibitors, and most showed significant inhibitory …
[HTML][HTML] Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis
I Cromwell, K van der Hoek, B Melosky… - Journal of Thoracic …, 2011 - Elsevier
Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …
Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach
V Hirsh - Current oncology, 2010 - mdpi.com
Historically, first-line treatment of non-small-cell lung cancer (NSCLC) has been based on
giving a limited number of cycles of chemotherapy to achieve tumour response or stable …
giving a limited number of cycles of chemotherapy to achieve tumour response or stable …